Downloads: 36

Files in This Item:
File Description SizeFormat 
cas.14692.pdf1.57 MBAdobe PDFView/Open
Title: Programmed cell death 1‐expressing CD56‐negative natural killer (NK) cell expansion is a hallmark of chronic NK cell activation during dasatinib treatment
Authors: Ishiyama, Ken‐ichi
Kitawaki, Toshio  kyouindb  KAKEN_id
Otsuka, Yasuyuki
Takaori‐Kondo, Akifumi
Kadowaki, Norimitsu
Author's alias: 石山, 賢一
北脇, 年雄
大塚, 泰幸
髙折, 晃史
Keywords: CD56
chronic myeloid leukemia
dasatinib
NK cell
PD-1
Issue Date: Feb-2021
Publisher: Wiley
Japanese Cancer Association
Journal title: Cancer Science
Volume: 112
Issue: 2
Start page: 523
End page: 536
Abstract: Dasatinib treatment markedly increases the number of large granular lymphocytes including natural killer (NK) cells in a proportion of Ph+ leukemia patients, which associates with a better prognosis. In-depth immune profiling of NK cells can predict therapeutic response in these patients. In the present study, we showed that CD56-negative (CD56neg) NK cells increased exclusively in cytomegalovirus-seropositive (CMV+) patients treated with dasatinib. The increase longitudinally paralleled with progressive differentiation of CD56dim NK cells during dasatinib therapy driven by CMV reactivation as shown by principal component analysis on 19 NK cell markers. The CD56neg NK cells showed downregulation of NK-activating receptors, upregulation of PD-1, and lower cytotoxicity and cytokine production, indicating that these cells are anergic and dysfunctional as seen in chronic infections with HIV-1 or hepatitis C virus. Moreover, cytolytic activity of CD56dim and CD56neg NK cells against leukemia cells was partially restored by nivolumab in proportion to the frequency of PD-1+ NK cells. The proportion of patients who achieved deep molecular responses at 2 years was significantly higher in dasatinib-treated patients with ≥3% CD56neg NK cells than in those with fewer CD56neg NK cells (54.5% vs 15.8%, P = .0419). These findings suggest that CD56neg NK cells may be an exhausted population induced by chronic activation through CMV reactivation during dasatinib therapy. Expansion of CD56neg NK cells is a hallmark of chronic NK cell activation in patients treated with dasatinib and may predict a better clinical outcome. Furthermore, PD-1 blockade may enhance anti-leukemia responses of such NK cells.
Rights: © 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
URI: http://hdl.handle.net/2433/277836
DOI(Published Version): 10.1111/cas.14692
PubMed ID: 33064914
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


This item is licensed under a Creative Commons License Creative Commons